novo nordisk oral glp 1 Semaglutide Approved to Reduce the Risk of Cardiovascular Events Novo Nordisk's oral GLP-1 drug
Description
Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity to shed, on average, 28 percent of their body weight - a substantial step up in...
This article explores the science behind these agents.
Tired of GLP-1 medications
We break down the link between the medication and this side effect, plus how to find relief.
Provider-guided care at our Bend clinic in the Old Mill
